Tourette syndrome (TS) is a heritable, neurodevelopmental disorder characterized by
rapid, paroxysmal stereotyped motor or vocal behaviors. Individuals with TS often
have poor psychosocial outcomes and comorbidity with major depression (
1
). First-line treatment for many cases of TS includes cognitive-behavioral interventions
and psychoeducation, while pharmacologic interventions include dopamine antagonists,
alpha2-adrenergic agonists, psychostimulants, anticonvulsants, and selective serotonin
reuptake inhibitors (
2
,
3
). Experimental interventions include repetitive transcranial magnetic stimulation,
electroconvulsive therapy (ECT), and deep brain stimulation.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Psychosocial outcome and psychiatric comorbidity in older adolescents with Tourette syndrome: Controlled study.Br J Psychiatry. 2010; 197: 36-44
- European clinical guidelines for Tourette syndrome and other tic disorders.Eur Child Adolesc Psychiatry. 2011; 20: 153-154
- Current controversies on the role of behavior therapy in Tourette syndrome.Mov Disord. 2013; 28: 1179-1183
- The Yale Global Tic Severity Scale: Initial testing of a clinician-rated scale of tic severity.J Am Acad Child Adolesc Psychiatry. 1989; 28: 566-573
- Response of major depression and Tourette׳s syndrome to ECT: A case report.Psychosom Med. 1998; 60: 528-529
- Electroconvulsive therapy in a patient with severe tic and major depressive episode.J Clin Psychiatry. 1990; 51: 34-35
- Long-term results of electroconvulsive therapy in severe Gilles de la Tourette syndrome.J ECT. 2011; 27: 145-147
- Advances in understanding and treatment of Tourette syndrome.Nat Rev Neurol. 2011; 7: 667-676
- Tourette׳s syndrome: From behaviour to biology.Lancet Neurol. 2005; 4: 149-159
- Cellular and molecular pathology in Tourette Syndrome.in: Martino D. Leckman J.F. Tourette Syndrome. Oxford Unity Press, New York2013: 205-220
- Recent advances in Tourette syndrome research.Trends Neurosci. 2006; 29: 175-182
- Functional immaturity of cortico-basal ganglia networks in Gilles de la Tourette syndrome.Brain. 2012; 135: 1937-1946
- Evaluation of basal ganglia and thalamic inflammation in children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection and Tourette syndrome: A positron emission tomographic (PET) study using 11C-[R]-PK11195.J Child Neurol. 2014; 30: 749-756
- Transcriptome analysis of the human striatum in Tourette syndrome.Biol Psychiatry. 2016; 79: 372-382
- Inflammatory cytokine-associated depression.Brain Res. 2014; 1617: 113-125
- Imaging onset and propagation of ECT-induced seizures.Epilepsia. 2007; 48: 238-244
- Focal network involvement in generalized seizures: New insights from electroconvulsive therapy.Epilepsy Behav. 2004; 5: 3-12
- Lessons learned from open-label deep brain stimulation for Tourette Syndrome: Eight cases over 7 years.Tremor Other Hyperkinet Mov (N Y) 3.pii:tre-03-170-4428-1. 2013;
Article info
Publication history
Published online: October 03, 2014
Identification
Copyright
© 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
